Skip to main content

Gene Logic Names New CEO; Affy Adds Director; Transgenomic Loses Director; Codon Hires CFO; and Others

NEW YORK (GenomeWeb News) – Gene Logic this week named Charles Dimmler its new CEO. Dimmler replaces Mark Gessler, who will maintain his position as chairman of the board of directors.
Dimmler has been on Gene Logic’s board of directors for 10 years, and has involved in biotechnology management and finance for 20.

Affymetrix has named Robert Wayman to its board of directors.
Wayman recently retired as executive vice president and CFO at Hewlett-Packard. He had also been a director at HP, Conway, and Sybase.

Parag Saxena resigned last week as a director of Transgenomic, the company said this week. Saxena also resigned from his duties on the company’s board-compensation and audit committees.

Codon Devices has appointed Daniel Geffken to the post of chief financial officer, the company said this week.
Geffken most recently was executive vice president and CFO at Konarka Technologies.

He has also served as CFO and having held positions involving fundraising, investor relations, and management at Transkaryotic Therapies, CytoTherapeutics, and Omnisonics Medical Technologies.

C. Robert Eaton has resigned from his post as president of MdBio, a non-profit group that promotes the growth of the bioscience industry in Maryland, MdBio said this week.
Julie Coons, CEO of the Tech Council of Maryland, will take Eaton’s place until a replacement is found.
Eaton, who worked for the organization for 10 years, will leave his job at the end of the month to “pursue opportunities in the private sector,” MdBio said.

The Burnham Institute for Medical Research has named Robert Zaugg vice president of business development, the institute said this week.
The La Jolla, Calif.-based non-profit operates three centers studying cancer, neurosciences, aging, infection, and inflammatory diseases.   
Zaugg has worked as an executive, consultant, or scientist at companies including DermAegis, GTS Proteomics, Triton Biosciences, Vical, and Teknekron.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.